ARTICLE | Finance
Epigenetic risk management
High risk of selective epigenetic modulators leads to stepwise Rodin financing
June 2, 2014 7:00 AM UTC
Given the challenge of finding safe molecules against epigenetic targets outside of cancer, Atlas Venture and Johnson & Johnson Development Corp. are taking a stepwise approach to financing Rodin Therapeutics Inc. In the past year the neurology company has done enough preclinical work to convince investors to put down the next chunk of cash via last week's $12.9 million series A round.
The investors launched Rodin in 2013 with an undisclosed seed round and a partnership with fellow founding investor Proteros biostructures GmbH, a CRO, to discover small molecule modulators selective for specific isoforms of epigenetic targets (see BioCentury, July 1, 2013)...